Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Phosphagenics — Investor Presentation (April 2018)
18 slides from Avecho Biotechnology's investor presentation, April 2018
Slide 1: Phosphagenics: Investor Presentation
April 2018 Phosphagenics: Investor Presentation www.phosphagenics.com (ASX : POH)
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation, and any representations made before, during or after the presentation, may include forward-looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or efficacy of, or potent
Slide 3: Phosphagenics Mission
Phosphagenics Innovative biopharmaceutical company headquartered in Australia Mission To become a leading biopharmaceutical company, utilising our TPM® delivery technology to develop innovative therapeutics that address unmet medical needs and enhance patients’ quality of life. 3
Slide 4: A snapshot of Phosphagenics
A snapshot of Phosphagenics • TPM® is a proprietary solubilisation / drug delivery technology combining multiple forms of Vitamin E (protected by 15+ patent Families) • Result of 15+ years R&D and over $100M investment • Pipeline of TPM® injectables with enhanced usability characteristics • TPM® pat
Slide 5: TPM is core to Phosphagenics' portfolio
TPM® is core to Phosphagenics’ portfolio Phosphagenics leverages TPM®’s unique properties, data and broad patent portfolio across multiple lucrative markets Highly versatile Phosphagenics with an excellent invented*, developed, stability and patented and is the Human safety profile Health sole globa
Slide 6: TPM can overcome key challenges for injectable drugs
TPM® can overcome key challenges for injectable drugs CHALLENGES “TPM® targets” • Solubilisation needs complex, toxic or • A safer and more natural excipient allergenic excipients Manufacturing • Improve stability reducing need to lyophilise • Unstable formulation needs lyophilisation • Allows previ
Slide 7: Human Health Injectable portfolio
Phosphagenics has a strong Human Health “Injectable” portfolio strengthened by the benefit of global partnerships The global Injectable Injectables Problems TPM® market is an immense account for with product can overcome opportunity1 more than quality cause important 80% of the 77% of sterile challe
Slide 8: Human Health Pain Product portfolio
Phosphagenics has a strong Human Health “Pain Product” portfolio strengthened by the benefit of global partnerships The global Pain market Opioids and Side effects TPM® is also a significant and abuse of can allow NSAIDs opportunity1 oral pain delivery of account for therapeutics pain therapy $62B $
Slide 9: Animal Health portfolio
Phosphagenics has a strong “Animal Health” portfolio driven by recent strong trial data The global Animal Over 250,000 TPM® Use of Feed Additive market is tons/year of antibiotics for significantly a 3rd major vitamins for live weight improve live opportunity1 livestock gain being weight gain/ feed
Slide 10: Personal Care portfolio with multiple partnerships
Phosphagenics’ “Personal Care” portfolio has multiple partnerships generating growing recurring revenues Vital ET® and Existing Dataset TPM® are in TPM® more than 100 Demand supports and Vital ET® in cosmetics exceeds10 Vital ET® as Personal Care worldwide tonnes/yr and anti-irritant & provides a pr
Slide 11: Phosphagenics' arbitration with Mylan
Phosphagenics’ arbitration with Mylan Signed agreements with Agila Specialties Private Ltd to develop and market 2011/12: Phosphagenics’ TPM®/Daptomycin injectable 2013: Strides Shasun (STR:IN NATL INDIA) sold Agila to Mylan (MYL (NASDAQ, TASE)) for ~US$1.4B 2016: Phosphagenics filed arbitration in
Slide 12: Board recommends shareholder return
Board of Directors recommends shareholder return* If Phosphagenics is successful and receives a material payment from Mylan, the Board intends to recommend a return of capital* (after costs): 50% 70% 30% of net cash of net cash of net cash Calculation: proceeds up to + proceeds + proceeds between gr
Slide 13: Delivered news flow and targeted newsflow over next 12 months
We have delivered consistent substantial news flow and target valuable newsflow over the next 12 months Patch options (2) and R&D Alliance deal (3) with Terumo Human Health Complete 2H 2016 R&D Agreement for new projects with Terumo. Human Health Complete ProPhase Arbitration Decision Personal Care
Slide 14: Experienced Management & Board with strong track record
Experienced Management & Board with strong track record of success Greg Collier, Chairman & Independent Director • 20+ years experience; current CEO of Invion (ASX: IVX) • Previous: CEO of ChemGenex (sold to Cephalon for $200M+) • 150 peer reviewed publications, 33 patents, Roche Award for Excellenc
Slide 15: Experienced Management & Board with strong track record
Experienced Management & Board with strong track record of success Anna Legg, CFO & Company Secretary • 20+ years financial experience; joined Phosphagenics in 2013 • Experience with establishment of international entities, statutory reporting, system development and financial modeling Paul Gavin, C
Slide 16: Phosphagenics is an exciting investment opportunity
Phosphagenics is a exciting investment opportunity Experienced Management / Board with strong track record of success Validated TPM® Technology through all three businesses • Portfolio including “world first” transdermal opioid patches, gels & injectables Multiple Commercialised Products and consist
Slide 17: Phosphagenics Key Statistics
Phosphagenics Innovative Biopharmaceutical Company Headquartered in Australia Key Statistics: ASX/OTCQX Code POH/PPGNY (listed 2004) Headquarters Melbourne, Australia Employees 12 Shares ~1.5 billion Cash $5.4M (18 Jan 2018) Revenue ~$1.2M (2017) Market Cap ~$20M (at $.012/share) 3 Business Units •
Slide 18: Melbourne Office contact details
www.phosphagenics.com Melbourne Office Unit A8, 2A Westall Road Dr Ross Murdoch, CEO & Managing Director Hallmarc Business Park rmurdoch@phosphagenics.com Clayton VIC 3168 Australia Dr Alex Stojanovic, VP BD & Commercial Tel: +61 3 9002 5000 astojanovic@phosphagenics.com Email: info@phosphagenics.co